Quick Answer

Retatrutide is an investigational once-weekly weight-loss medication being developed by Eli Lilly. What makes it different is that it activates three hormone pathways—GLP-1, GIP, and glucagon—instead of one or two.

The Phase 3 results released so far are impressive. In the TRIUMPH-1 obesity trial, participants receiving the highest studied dose lost an average of 28.3% of their body weight at 80 weeks. Among participants with a starting BMI of 35 or higher who continued into an extension, average weight loss reached 30.3% at 104 weeks.

But there is an equally important fact patients need to understand:

Retatrutide is not FDA-approved.

As of August 2026, it remains an investigational medication. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. Products currently being advertised online as “retatrutide” are not an FDA-approved version of this medication.

The science is exciting. But exciting science and an approved medication are two different things.

Key Takeaways

• Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
• Phase 3 obesity results have shown average weight loss approaching 30% at the highest studied doses and durations.
• Recent Phase 3 trials also showed substantial weight loss in people with type 2 diabetes and in people with established cardiovascular disease.
• Retatrutide remains investigational and is not FDA-approved.
• Lilly currently states that legitimate retatrutide is available only through its clinical trials.
• In August 2026, Lilly sued six companies it alleges were illegally selling products represented as retatrutide.
• The real story is bigger than another weight-loss medication. Retatrutide may represent the next step in our ability to influence the physiology that regulates appetite, metabolism, and body weight.

“Doctor, Can You Get Me Retatrutide?”

Over the last several years, I have watched the conversation around obesity medicine change dramatically.

Years ago, patients would come into my office and ask:

“What diet should I try?”

Then it became:

“What do you think about Ozempic?”

Then:

“Is Mounjaro better?”

And now I am increasingly hearing another question:

“Doctor, what about retatrutide?”

Some patients have already seen advertisements for it online. Others have watched videos describing it as the next “miracle” weight-loss drug. And some have even found websites claiming they can purchase it today.

My answer is usually:

I’m very excited about retatrutide. But I’m not ready to prescribe it.

Not because the science isn’t impressive.

It is.

But because one of the most important lessons in medicine is learning to separate promising science from proven, regulated medicine.

Retatrutide is giving us a fascinating glimpse into where obesity treatment may be heading.

To understand why, however, we first need to understand something much more important:

Why does the human body fight weight loss in the first place?

Obesity Is Not Simply a Willpower Problem

For decades, weight loss was presented as a simple math equation:

Eat less.

Exercise more.

Burn more calories than you consume.

There is truth in that equation. Energy balance matters.

But anyone who has treated obesity for long enough realizes that this explanation is incomplete.

The human body is not a calculator.

It is a biological system designed to survive.

When you lose weight, your body doesn’t necessarily celebrate your success.

Sometimes it tries to reverse it.

Hunger can increase.

Fullness signals can weaken.

Energy expenditure can decline.

Food can suddenly become much more interesting.

This is why someone can lose 30 pounds and then feel as though their own body is negotiating against them every day to regain it.

I sometimes explain this to patients using a thermostat.

Imagine setting your house to 72 degrees.

Open every window during winter and the temperature falls.

What happens?

The furnace doesn’t say, “Congratulations on lowering the temperature.”

It turns on.

Your body has its own complicated version of that thermostat.

When weight falls, multiple hormonal and neurological signals can respond in ways designed to preserve energy and restore weight.

That doesn’t mean weight loss is impossible.

It means that successful obesity treatment sometimes requires us to work with the physiology rather than constantly fighting against it.

That is what made GLP-1 medications such an important development.

And it is what makes retatrutide particularly interesting.

From One Hormone to Two—and Now Three

To understand retatrutide, think about an orchestra.

Your metabolism isn’t controlled by one instrument.

It is an orchestra of signals traveling between your intestine, pancreas, liver, fat tissue, muscles, and brain.

Among those signals are hormones called GLP-1, GIP, and glucagon.

Current medications have already shown us what can happen when we influence some of these pathways.

Semaglutide medications primarily activate the GLP-1 receptor.

Tirzepatide activates two receptors: GIP and GLP-1.

Retatrutide goes one step further.

It activates:

GIP + GLP-1 + glucagon.

Three instruments in the metabolic orchestra instead of one or two.

That is why retatrutide is often called a triple agonist.

And the third component—glucagon—is especially interesting.

Wait—Doesn’t Glucagon Raise Blood Sugar?

This is where patients sometimes get confused.

If you’ve learned anything about diabetes, you may have heard that insulin lowers blood sugar while glucagon tends to raise it.

So why would we intentionally stimulate a glucagon receptor in someone trying to improve metabolic health?

Because hormones rarely have only one job.

Glucagon participates in energy regulation and metabolism in several tissues. Researchers are investigating whether carefully combining glucagon receptor activity with GLP-1 and GIP activity can influence energy balance in ways that complement appetite reduction and metabolic control.

Think of it like driving a car.

GLP-1 and GIP may help influence how much fuel comes into the system and how the body responds to that fuel.

The glucagon component may influence how the body manages and uses stored energy.

That doesn’t mean “more glucagon equals more weight loss.” Human physiology is much more complicated than that.

The important idea is that retatrutide was designed to influence multiple coordinated metabolic pathways at the same time.

And so far, the clinical results suggest that this approach may be very powerful.

How Much Weight Are People Losing With Retatrutide?

This is where the numbers become difficult to ignore.

In Lilly’s Phase 3 TRIUMPH-1 trial, adults with obesity or overweight without diabetes received different doses of retatrutide.

At 80 weeks, average weight loss was:

• 19.0% with 4 mg
• 25.9% with 9 mg
• 28.3% with 12 mg

Participants receiving 12 mg lost an average of approximately 70 pounds from an average starting weight of about 249 pounds. Even more striking, 45.3% of participants receiving 12 mg lost at least 30% of their body weight.

And researchers learned something else.

Some participants with a starting BMI of at least 35 continued treatment in an extension to 104 weeks.

Those receiving the highest-dose regimen reached an average weight reduction of 30.3%—approximately 85 pounds from their average starting weight.

Those are extraordinary numbers for medical obesity treatment.

But I want to emphasize one word:

Average.

Some people lost considerably more.

Some lost less.

Some discontinued treatment.

No medication guarantees that an individual patient will reproduce the average result of a clinical trial.

That distinction matters.

Weight Loss Is Only Part of the Story

This may actually be the most interesting part of the retatrutide research.

Obesity isn’t simply about the number on the scale.

Excess adipose tissue—particularly visceral fat around the abdominal organs—can affect blood pressure, insulin sensitivity, inflammation, sleep apnea, fatty liver disease, joint stress, and cardiovascular health.

So when I evaluate an obesity medication, I don’t simply ask:

“How many pounds did people lose?”

I want to know:

What happened to their health?

In TRIUMPH-1, Lilly reported improvements in several cardiovascular risk factors, including waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and hs-CRP, a marker associated with inflammation.

The study also included groups of patients with obesity-related knee osteoarthritis and obstructive sleep apnea. Lilly reported substantial improvements in both conditions alongside weight reduction.

That makes physiological sense.

Imagine carrying a 50-pound backpack everywhere you go.

Up the stairs.

Into bed.

Across the parking lot.

Through your workday.

Now imagine taking that backpack off.

Your knees experience less mechanical stress.

Breathing during sleep may improve.

Movement becomes easier.

Exercise becomes more realistic.

And improvements in metabolic health can occur simultaneously.

That is why I prefer to think about obesity treatment not simply as weight loss, but as health optimization through improved body composition and metabolic physiology.

The scale is one measurement.

The real goal is a healthier human being.

What About People With Diabetes?

Weight loss medications sometimes perform differently in people with type 2 diabetes, and historically this population can lose somewhat less weight than people without diabetes.

That makes the recent Phase 3 data particularly interesting.

In the July 2026 TRIUMPH-2 results, adults with overweight or obesity and type 2 diabetes receiving the highest retatrutide dose lost an average of 20.8% of their body weight at 80 weeks, while A1C fell by as much as an average of 1.6 percentage points.

Earlier Phase 3 diabetes results from TRANSCEND-T2D-1 also demonstrated meaningful reductions in both A1C and body weight.

Again, this reinforces something I’ve told patients for years:

Obesity and diabetes are not two completely separate diseases living in different rooms.

They often share the same metabolic house.

Insulin resistance, visceral fat, appetite regulation, liver metabolism, muscle mass, sleep, activity, and genetics interact with one another.

Improve the underlying physiology and multiple parts of the house can improve together.

What About Cardiovascular Disease?

Another important Phase 3 study, TRIUMPH-3, evaluated adults with obesity and established cardiovascular disease—with or without type 2 diabetes.

At the highest studied dose, participants lost an average of 22.6% of their body weight at 80 weeks, according to Lilly’s July 2026 topline results.

That is an important population.

These aren’t simply people trying to lose weight before vacation.

They are patients who already have cardiovascular disease.

We still need the full scientific picture, including longer-term outcomes and peer-reviewed publication of detailed results. Weight reduction and improvements in risk factors do not automatically prove that a medication prevents heart attacks or strokes.

But studying these medications in patients with real cardiometabolic disease represents exactly where obesity medicine should be heading.

The goal should never be simply to make someone smaller.

The goal is to make someone healthier.

So Why Can’t I Prescribe Retatrutide Today?

Because promising clinical trial results do not equal FDA approval.

As of August 2026, retatrutide remains an investigational medication.

Lilly says it now has positive results from five Phase 3 studies and plans to submit retatrutide to the FDA for U.S. approval in Q1 2027.

The FDA will then evaluate the evidence regarding effectiveness, safety, manufacturing, quality, dosing, labeling, and other factors before deciding whether the medication should be approved.

Until that process occurs, there is no FDA-approved retatrutide product available for physicians to routinely prescribe.

And this brings us to the part of the story that concerns me much more than the excitement surrounding the medication.

“But Doctor, I Found Retatrutide Online”

This conversation is already happening.

Search online and you may encounter websites, peptide sellers, clinics, or social-media advertisements claiming to offer retatrutide.

That creates an understandable question:

“If people are already selling it, doesn’t that mean it’s available?”

No.

Lilly currently states that retatrutide is legally available only to participants in its clinical trials and that products being sold to consumers outside those trials cannot be verified as to their safety, purity, or dosing.

This distinction became even more important in August 2026.

On August 12, Lilly filed lawsuits against six U.S. companies that it alleges were illegally selling products represented as retatrutide while the medication remains investigational.

This isn’t about whether retatrutide is good or bad.

It is about knowing what is actually inside the vial.

The Restaurant Kitchen Test

Here’s how I explain this to patients.

Imagine hearing about an incredible new restaurant that hasn’t opened yet.

The chef is still developing the menu.

Food critics participating in private tastings say the meals are extraordinary.

Then someone sets up a table in the parking lot with containers labeled:

“Food from the new restaurant.”

Maybe it is.

Maybe it isn’t.

The problem is that you have no reliable way of knowing who made it, what ingredients were used, how it was prepared, or whether it came from that restaurant at all.

That’s essentially the issue with buying an investigational medication from an unauthorized source.

The name on the vial does not prove what is inside the vial.

And when something is being injected into your body, that distinction matters enormously.

Why Clinical Trials Matter

Patients sometimes think of clinical trials as bureaucratic hurdles standing between them and a new medication.

I see them differently.

Clinical trials are how we learn what we don’t yet know.

• How effective is the medication?
• What dose works best?
• What side effects occur?
• How frequently do they occur?
• Who should not take it?
• How quickly should the dose increase?
• What happens after one year?
• What happens after two years?
• Are there uncommon complications that don’t become obvious until thousands of people have been treated?

Those questions cannot be answered by social-media enthusiasm.

They require carefully collected data.

That is why I can simultaneously say:

“Retatrutide may be one of the most exciting obesity medications I’ve seen.”

and

“I would not recommend buying supposed retatrutide online today.”

Those statements are not contradictory.

That is what responsible medicine looks like.

What Side Effects Have Been Seen?

Like other medications that act on incretin pathways, retatrutide has most commonly been associated with gastrointestinal side effects.

In the Phase 3 program, these have included symptoms such as nausea, diarrhea, vomiting, constipation, and decreased appetite, with gastrointestinal effects generally occurring more often at higher doses and during dose escalation.

This is another reason dosing matters.

With metabolic medications, more is not automatically better.

The objective isn’t to reach the highest dose as quickly as possible.

The objective is to find an effective and tolerable dose that produces sustainable improvement.

Obesity treatment is a marathon.

Winning the first mile doesn’t help if you can’t finish the race.

Could Retatrutide Replace Today’s GLP-1 Medications?

Possibly for some patients someday.

But I wouldn’t think about it that way yet.

Semaglutide and tirzepatide already have extensive clinical experience and approved indications. Retatrutide is still completing the journey through clinical development and regulatory review.

Medicine rarely progresses by discovering one medication that makes everything before it obsolete.

Instead, we build a larger toolbox.

One patient may respond beautifully to one medication.

Another may need something different.

Some patients may prioritize maximum weight reduction.

Others may prioritize tolerability.

Some have diabetes.

Some have cardiovascular disease.

Some need to lose 100 pounds.

Others need to lose 25.

The future of obesity medicine will probably involve more choices, not one universal winner.

And that’s good news.

The Medication Is Powerful. But It Still Isn’t the Whole Treatment.

There is another conversation we need to have as these medications become increasingly powerful.

If someone loses 70 or 80 pounds, what exactly are they losing?

We want to lose excess fat—particularly unhealthy visceral fat.

We do not want unnecessary loss of muscle.

Muscle is metabolically valuable tissue.

It supports glucose metabolism.

It protects mobility.

It supports bone health.

It helps maintain strength and independence as we age.

That means effective obesity treatment should increasingly focus on body composition, not simply body weight.

• Protein intake matters.
• Resistance training matters.
• Sleep matters.
• Hormonal health may matter.
• Physical activity matters.
• Nutrition quality matters.
• Long-term maintenance matters enormously.

A medication can help change the physiology that has been fighting against weight loss.

But medication should create an opportunity to build a healthier body—not simply a lighter one.

What This Means for You

If you are currently doing well on an FDA-approved obesity medication, the emergence of retatrutide does not mean you should stop what is working and wait for the next medication.

If your current treatment is helping you lose excess fat, improve blood pressure, control blood sugar, move better, sleep better, and improve your overall health, those benefits are happening today.

Don’t sacrifice today’s progress while waiting for tomorrow’s technology.

If retatrutide eventually receives FDA approval, we will have more information about its safety, dosing, appropriate patient selection, and how it compares with other available therapies.

At that point, physicians and patients can make thoughtful decisions together.

Until then, I would watch the science with optimism—and resist the temptation to get ahead of it.

Myth vs. Fact

Myth: Retatrutide is already available because clinics are advertising it online.

Fact: Retatrutide remains investigational and is not FDA-approved. Lilly states that legitimate retatrutide is currently available only through its clinical trials.

Myth: Retatrutide is simply a stronger version of Ozempic.

Fact: Retatrutide is pharmacologically different. It activates three hormone receptors—GIP, GLP-1, and glucagon—while semaglutide primarily targets GLP-1.

Myth: Everyone taking retatrutide lost 28% to 30% of their body weight.

Fact: Those numbers represent averages from specific trial populations and treatment regimens. Individual results varied.

Myth: If retatrutide causes more weight loss, it automatically means it is the best medication for everyone.

Fact: Effectiveness is only one part of choosing treatment. Safety, tolerability, medical history, body composition, metabolic health, cost, access, and long-term sustainability all matter.

Myth: Once medications become this powerful, diet and exercise no longer matter.

Fact: They matter even more. As weight loss becomes greater, preserving muscle, improving nutrition, maintaining physical activity, and creating sustainable habits become increasingly important.

Frequently Asked Questions

Is retatrutide FDA-approved?

No. As of August 2026, retatrutide remains investigational and has not been approved by the FDA.

When could retatrutide become available?

Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027. Submission does not guarantee approval or establish an exact launch date.

How does retatrutide work?

Retatrutide is a single molecule designed to activate three hormone receptors: GIP, GLP-1, and glucagon. These pathways participate in appetite regulation, glucose metabolism, and energy balance.

How much weight did people lose?

In TRIUMPH-1, participants receiving 12 mg lost an average of 28.3% of body weight at 80 weeks. In an extension involving participants who began with BMI ≥35, average weight loss reached 30.3% at 104 weeks with the highest-dose regimen.

Does retatrutide help diabetes?

Phase 3 trials have shown meaningful improvements in A1C and body weight among participants with type 2 diabetes, but retatrutide remains investigational.

Can I buy retatrutide from a compounding pharmacy or peptide website?

There is currently no FDA-approved retatrutide product for routine public use. Lilly states that retatrutide is legally available only through its clinical trials and warns that products sold elsewhere cannot be verified for safety, purity, or dosing.

Should I wait for retatrutide before starting weight-loss treatment?

For most patients who medically qualify for treatment today, I would not postpone improving their health simply because another medication may become available in the future. Your physician can help determine which currently available options are appropriate for you.

Bottom Line

Retatrutide may represent an important next chapter in obesity medicine.

The Phase 3 results are impressive.

Average weight loss approaching 30% would have been difficult to imagine from medication alone not very long ago.

But the bigger story isn’t a competition over which injection produces the largest number on the scale.

The bigger story is that we are becoming better at understanding why the body gains weight, why it defends that weight, and how multiple hormonal systems regulate appetite and metabolism.

That understanding gives us better tools.

And better tools give patients more opportunities.

Retatrutide may eventually become one of those tools.

But it isn’t one yet.

So when a patient asks me today:

“Doctor, are you excited about retatrutide?”

My answer is absolutely yes.

And when they ask:

“Should I buy some online?”

My answer is equally clear:

No.

Be excited about the science.

Follow the evidence.

And give medicine enough time to determine whether the promising drug being studied today becomes the safe, regulated treatment we can confidently use tomorrow.

That’s not being behind the curve.

That’s practicing good medicine.

The Delight Difference

At Delight Medical & Wellness Center, we have been treating obesity as a medical and metabolic condition long before today’s weight-loss medications became household names.

Our approach goes beyond asking how many pounds someone has lost.

We look at body composition, visceral fat, muscle mass, insulin resistance, cardiovascular risk, hormones, sleep, nutrition, physical activity, and long-term quality of life.

Because losing weight is not the final destination.

Improving health is.

Modern medications can be extraordinarily useful tools when appropriately prescribed and monitored. But the best results occur when we combine those tools with an understanding of the individual patient and the physiology driving their health.

That’s the difference between simply treating a number on the scale and practicing Health Optimization Medicine.

About Dr. Payam Kerendian

Dr. Payam Kerendian, DO, is the founder of Delight Medical & Wellness Center in Los Angeles, California.

His practice focuses on Health Optimization Medicine, including obesity and metabolic health, hormone optimization, cardiovascular risk reduction, body composition, preventive medicine, and healthy aging.

For more than two decades, Dr. Kerendian has helped patients understand the physiology behind their health so they can make better decisions today—and remain healthier, stronger, and more active for years to come.

His philosophy is simple:

Understand your physiology. Optimize your health. Improve your quality of life.

Ready to Improve Your Metabolic Health?

You don’t need to wait for the next generation of medication to begin improving your health.

If you’re struggling with obesity, insulin resistance, metabolic health, or maintaining weight loss, the first step is understanding why your body is responding the way it is.

At Delight Medical & Wellness Center, we can evaluate your current health, body composition, metabolic risk factors, and available treatment options to develop a personalized strategy built around more than simply losing pounds.

Because the most exciting development in obesity medicine isn’t one particular medication.

It’s that we’re finally learning how to work with the body’s physiology instead of asking patients to spend their lives fighting against it.